Improved CD4+ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: A randomized trial
Leroux-Roels, Isabel, Forgus, Sheron, De Boever, Fien, Clement, Frédéric, Demoitié, Marie-Ange, Mettens, Pascal, Moris, Philippe, Ledent, Edouard, Leroux-Roels, Geert, Ofori-Anyinam, Opokua
Published in Vaccine (19.04.2013)
Published in Vaccine (19.04.2013)
Get full text
Journal Article
Priming with AS03A -adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: An open non-randomised extension of a double-blind randomised primary study
Leroux-Roels, Isabel, Roman, François, Forgus, Sheron, Maes, Cathy, De Boever, Fien, Dramé, Mamadou, Gillard, Paul, van der Most, Robbert, Van Mechelen, Marcelle, Hanon, Emmanuel, Leroux-Roels, Geert
Published in Vaccine (08.01.2010)
Published in Vaccine (08.01.2010)
Get full text
Journal Article
Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: An open non-randomised extension of a double-blind randomised primary study
Leroux-Roels, Isabel, Roman, François, Forgus, Sheron, Maes, Cathy, De Boever, Fien, Dramé, Mamadou, Gillard, Paul, van der Most, Robbert, Van Mechelen, Marcelle, Hanon, Emmanuel, Leroux-Roels, Geert
Published in Vaccine (08.01.2010)
Published in Vaccine (08.01.2010)
Get full text
Journal Article
An Adjuvanted, Low-Dose, Pandemic Influenza A (H5N1) Vaccine Candidate Is Safe, Immunogenic, and Induces Cross-Reactive Immune Responses in Healthy Adults
Levie, Karin, Leroux-Roels, Isabel, Hoppenbrouwers, Karel, Kervyn, Anne-Diane, Vandermeulen, Corinne, Forgus, Sheron, Leroux-Roels, Geert, Pichon, Sylvie, Kusters, Inca
Published in The Journal of infectious diseases (01.09.2008)
Published in The Journal of infectious diseases (01.09.2008)
Get full text
Journal Article
An Adjuvanted, Low-Dose, Pandemic Influenza A (H5N1) Vaccine Candidate Is Safe, Immunogenic, and Induces Cross-Reactive Immune Responses in Healthy Adults. Commentary
POLAND, Gregory A, SAMBHARA, Suryaprakash, KUSTERS, Inca, LEVIE, Karin, LEROUX-ROELS, Isabel, HOPPENBROUWERS, Karel, KERVYN, Anne-Diane, VANDERMEULEN, Corinne, FORGUS, Sheron, LEROUX-ROELS, Geert, PICHON, Sylvie
Published in The Journal of infectious diseases (2008)
Get full text
Published in The Journal of infectious diseases (2008)
Journal Article